Leticia Alves Soares, Cynthia Paniagua, Julie Nguyen, Ajla Kojic, Elena Rose Sanfrey, Madison Emilee Reyome, Liliana Aguayo, Elisabeth Lilian Pia Sattler
{"title":"The Role of Glucagon-Like Peptide-1 Receptor Agonists in Post ST-Segment Elevation Myocardial Infarction Care: A Scoping Review.","authors":"Leticia Alves Soares, Cynthia Paniagua, Julie Nguyen, Ajla Kojic, Elena Rose Sanfrey, Madison Emilee Reyome, Liliana Aguayo, Elisabeth Lilian Pia Sattler","doi":"10.1007/s40471-025-00375-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>This scoping review synthesizes current evidence on glucagon-like peptide-1 receptor agonist (GLP-1RA) use after ST-elevation myocardial infarction (STEMI), highlighting their potential as adjunctive therapy.</p><p><strong>Recent findings: </strong>Ten studies investigated exenatide and liraglutide in adults with STEMI, evaluating imaging, clinical, mechanistic, and safety outcomes. GLP-1RA use was safe and well tolerated. Exenatide demonstrated improvements in infarct size, myocardial salvage, and cardiac function, although two trials in broader STEMI populations reported no post-infarction improvements. Across three trials, liraglutide was associated with improved myocardial salvage, infarct size, left ventricular ejection fraction, stroke volume and no-reflow, supported by favorable biomarker changes, but without significant reductions in major cardiovascular events.</p><p><strong>Summary: </strong>While most existing evidence is based on studies with limited generalizability, GLP-1RA use shows promise in improving post-STEMI outcomes. The consistent benefits reported support the need for larger, multicenter trials to clarify GLP-1RA role in cardioprotection and long-term outcomes.</p>","PeriodicalId":94310,"journal":{"name":"Current epidemiology reports","volume":"12 1","pages":"22"},"PeriodicalIF":3.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12602557/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current epidemiology reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40471-025-00375-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose of review: This scoping review synthesizes current evidence on glucagon-like peptide-1 receptor agonist (GLP-1RA) use after ST-elevation myocardial infarction (STEMI), highlighting their potential as adjunctive therapy.
Recent findings: Ten studies investigated exenatide and liraglutide in adults with STEMI, evaluating imaging, clinical, mechanistic, and safety outcomes. GLP-1RA use was safe and well tolerated. Exenatide demonstrated improvements in infarct size, myocardial salvage, and cardiac function, although two trials in broader STEMI populations reported no post-infarction improvements. Across three trials, liraglutide was associated with improved myocardial salvage, infarct size, left ventricular ejection fraction, stroke volume and no-reflow, supported by favorable biomarker changes, but without significant reductions in major cardiovascular events.
Summary: While most existing evidence is based on studies with limited generalizability, GLP-1RA use shows promise in improving post-STEMI outcomes. The consistent benefits reported support the need for larger, multicenter trials to clarify GLP-1RA role in cardioprotection and long-term outcomes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
